Download as PDF, PPTX
- 1 / 30
- 2 / 30
- 3 / 30
- 4 / 30
![Page 3 Biotechnology Industry Report 2017 | Beyond borders
In the dynamic biotech landscape, the only certainty is
uncertainty
“I can’t think of a period that has been
characterized by so much uncertainty as the past
six to nine months. … The uncertainty is a factor
that comes up in every board meeting I attend.”
– Alan Mendelson, Partner
Latham and Watkins
Successful companies have “learned to filter that
[uncertainty] out and focus on the things that are
right for the company. There may be tax reform.
There may be repatriation. But you can’t count on
it – and you can’t wait for it either.”
– John Milligan, CEO
Gilead Sciences](https://image.slidesharecdn.com/beyondbordersdeck-170809074911/85/EY-Biotechnology-Report-2017-Beyond-borders-Staying-the-course-4-320.jpg)
- 5 / 30
- 6 / 30
- 7 / 30
- 8 / 30
- 9 / 30
- 10 / 30
- 11 / 30
- 12 / 30
- 13 / 30
- 14 / 30
- 15 / 30
- 16 / 30
- 17 / 30
- 18 / 30
- 19 / 30
- 20 / 30
Skip to main content
Uploaded byEY
EY Biotechnology Report 2017: Beyond borders - Staying the course
The biotechnology industry remained strong in 2016 despite some declines and uncertainties. While industry financing dipped 27% from 2015, research and development spending hit a new record. Merger and acquisition activity was also robust despite a decline in upfront deal commitments. Looking ahead, biotechnology companies will need to navigate increasing complexity around issues like product reimbursement, research and development efficiency, digital strategies, dealmaking, and financing volatility. The ability to adapt to these shifting environments will be key to future success.
